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17  The protein epitope mimetic approach 
to protein-protein interaction inhibitors
John A. Robinson and Kerstin Moehle
17.1 Introduction
The design of small-molecule protein epitope mimetics is now widely recognized as 
a promising structure/mechanism-based approach to the discovery of protein-protein 
interaction (PPI) inhibitors. Progress in the fi eld has been driven, on the one hand, by 
the enormous increase in the knowledge base of PPIs, arising from high throughput 
genomic and proteomic methods (Lehne and Schlitt 2009; Stumpf et al. 2008), and 
on the other, by the massive growth in the 3D structural database of protein-protein 
complexes. The key scientifi c challenge is to convert this structural and functional in-
formation, through a rational molecular design process, into new PPI inhibitors with 
potential value in chemical biology, or in drug and vaccine discovery. Ideally, structural 
information on PPIs should be combined with an understanding of the mechanism(s) of 
PPIs, to aid the design process. In this review article, we begin with a short overview of 
recent mechanistic studies of PPIs. Following this, an overview is provided of methods 
now available for the discovery of PPI inhibitors, in particular, based on the protein 
epitope mimetic approach.
17.2 Mechanisms of protein-protein interactions
Protein-protein interfaces are often quite large (in the range 600 to ~2,500 Å2 on each 
side) (Conte et al. 1999; Jones and Thornton 1996), and although they are never really 
fl at, they do lack well-defi ned binding pockets of the type characteristic of enzyme 
active sites. It is probably worthwhile to differentiate between inhibitors targeting en-
zyme active sites and those directed toward PPIs. Enzymes have evolved to catalyze 
chemical reactions, mostly by binding tightly to the reaction transition state (TS). In 
other words, the required complementarity between the molecule undergoing reaction 
and the packing within the protein are most effi cient in the enzyme-TS complex. Based 
upon comparisons of reaction rates in enzyme catalyzed and noncatalyzed processes, 
it has been estimated that enzyme-TS complexes typically have dissociation constants 
in the range 10-12 M to 10-20 M (average 10-16±4 M), which is much greater than expected 
from the surface areas of TSs (Zhang and Houk 2005), in particular for those enzymes 
that operate by noncovalent interactions with their substrate(s) (Smith et al. 2009). 
Many active site-directed enzyme inhibitors act as structural analogues of the TS, and 
in optimal cases may achieve similar levels of complementarity and affi nity with the 
enzyme. The complementarity between the protein and TS typically includes a network 
of interactions extending into the protein shell surrounding the active site. This view is 
supported by recent studies with the enzyme purine nucleoside phosphorylase , which 
provided evidence for conformational collapse in the protein around a potent inhibitor 
in the active site due to its structural similarity to the TS (Edwards et al. 2010). Thus, with 
enzymes, improved packing and positive cooperativity in binding to the TS architecture 
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may involve an extensive network of interactions, perhaps extending some way into the 
protein shell around the active site (Williams 2010).
For many PPIs, average dissociation constants tend to be in the micromolar to nano-
molar range, not because higher affi nities are impossible, but because in many cases 
no strong evolutionary pressure exists for further affi nity maturation, as pointed out 
already for the case of antibody-antigen interactions (Foote and Eisen 1995). The theo-
retical diffusion-limited association rate for two molecules in solution is likely to be 
around 5  109 M-1 s-1 (the Einstein-Smoluchowski limit [Berg and von Hippel 1985]). 
Many PPIs in solution have association rates that are slower (in the range 104−107 
M-1 s-1 (Harel et al. 2007; Karlsson et al. 1991; Raman et al. 1992), although electro-
static steering effects can lead to substantially faster association rates (Gabdoulline and 
Wade 2002; Schreiber 2002; Schreiber and Fersht 1993, 1996; Selzer and Schreiber 
1999). A minimalist three-state model for protein-protein association was suggested, 
based on Brownian dynamics simulations, with a fi rst rapid diffusion controlled for-
mation of an encounter complex, in which a protein pair surrounded and trapped 
by a solvent cage undergoes multiple collisions and rotational reorientation during 
each encounter (Gabdoulline and Wade 2002; Northrup and Erickson 1992; Northrup 
et al. 1988; Selzer and Schreiber 2001; Tang et al. 2006). In a second rate-determining 
step, the two proteins rearrange to the fi nal stereospecifi c bound state, which might be 
rate-limited by conformational transitions and desolvation steps, amongst other things 
(Harel et al. 2007). Assuming that a lifetime for a protein-protein complex beyond 
20–30 min would (in many cases) bring little signifi cant extra biological advantage, an 
effective limit for the off-rate can be fi xed at 10-3 to 10-4 s-1, which would in turn give a 
ceiling on affi nity around 10-9 to 10-10 M. Enzyme inhibitor design based on mimicry of 
TSs may, in principle, tap-into a higher potential binding energy (average Kd 10-16±4 M) 
focused at an active site whose architecture is often complementary to that of a 
 small-molecule ligand.
The cores of monomeric proteins are stabilized consistently by hydrophobic interac-
tions . At some protein interfaces, hydrophobic forces play an important role (e.g. human 
growth hormone [hGH]-hGH-receptor [hGHR] complex ]Wells 1996]), but in others 
mainly polar or even charge-charge interactions seem to be dominant (e.g. barnase-
barstar) (Tsai et al. 1996, 1997). There appears to be no signifi cant difference in the 
chemistry or geometry of individual interactions at protein interfaces compared to the 
cores of folded monomers. However, side-chain-to-side-chain interactions are more 
frequent at protein interfaces compared to protein cores (Cohen et al. 2008). A num-
ber of studies have pointed out that energetically important residues at interfaces (hot 
spots – Figure 17.2, further on in this chapter) are enriched particularly in tryptophan, 
tyrosine and arginine, while some other amino acids are found very rarely in hot-spots 
(Val, Leu, Ser, Thr) (Bogan and Thorn 1998; Hu et al. 2000; Ma et al. 2003; Padlan 
1990). The preference for Trp, Tyr and Arg may be due, at least in part, to the ability of 
these side-chains to engage simultaneously in several types of favorable interactions, 
which in turn facilitate the creation of interaction networks at protein interfaces (see fur-
ther on in this section). Recently, minimalist combinatorial libraries based on restricted 
amino acid usage have been used to identify synthetic protein interfaces (Kossiakoff and 
Koide 2008). For example, interfaces built using just two different amino acids (Tyr/Ser) 
in the context of antibody CDR loops are suffi cient to produce antibody fragments with 
high affi nity and specifi city for protein targets (Gilbreth et al. 2008).
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Alanine-scanning mutagenesis led in 1995 to the identifi cation of so-called hot- 
residues located within “hot-spots” that have since been found in many protein-protein 
interfaces (Clackson and Wells 1995; Clackson et al. 1998; Moreira et al. 2007; Schrei-
ber and Fersht 1995). Ala mutations that reduce affi nity by >10-fold indicate a hot-
residue making a disproportionately large contribution to the binding energy. Such hot 
residues often cluster at the center of interfaces, constitute less than half of the contact 
surface, and are surrounded by other residues, which by this defi nition, contribute rela-
tively little in binding energy (DeLano 2002; Keskin et al. 2005; Reichmann et al. 2007). 
Not surprisingly, hot spots have become a major focus of interest in PPI inhibitor design 
(Wells and McClendon 2007). One mechanistic interpretation of hot-spots is that the 
peripheral residues serve as an O-ring to exclude solvent from the center, which would 
generate a lower effective dielectric and strengthen hydrogen-bonding and other elec-
trostatic interactions (Bogan and Thorn 1998). Similar effects are known to be important 
in enzyme catalysis, where water exclusion from the active site is often important for 
catalytic effi ciency. However, an alternative view has been proposed, where an interac-
tion deleted by Ala mutagenesis in the periphery might be more easily compensated by 
a bridging water molecule, and hence causes less loss in stability (Janin 1999). From 
structural studies it is known that protein interfaces contain on average more bound 
water molecules than are found in the core of a folded protein. Modeling studies have 
suggested that both effects may be operative in some cases (Kortemme and Baker 2002). 
In one mutagenesis study, it was possible to improve the affi nity of a PPI from a Kd of 23 
nM to 0.15 nM through mutations in a VH domain interacting with its protein antigen 
(Koide et al. 2007). In this case, a crystallographic study suggested that the mutations 
did not expand the antibody-antigen interface, but rather induced an extended network 
of interactions, and included additional hot residues at the periphery (not the center) 
of the epitope . These results indicate that although the O-ring architecture may occur 
frequently, it is not a prerequisite for high affi nity PPIs.
More recently, double mutant cycle analyses with selected PPIs have suggested 
that interfaces between proteins are often built in a modular fashion. Double mu-
tant cycles may reveal whether the contributions from a pair of mutated residues 
are additive or whether the energetic effects are coupled through neighboring resi-
dues (Albeck et al. 2000). In this way, the interface between TEM1-ß-lactamase and 
ß- lactamase inhibitor protein (KD 1 nM) was shown to have a modular architecture 
made up of clusters of residues with strong intracluster connections and weak inter-
cluster connections (Reichmann et al. 2005). The individual residue clusters appeared 
to be largely independent of each other energetically. A high degree of cooperativity 
within each cluster was apparent, to the point that in one case the deletion of an en-
tire cluster had little impact on the structure of the interface, whereas single mutations 
within a cluster could lead to structural rearrangements of their cluster (Potapov et al. 
2008). Computational analyses have also revealed that hot-spot residues may be clus-
tered locally within tightly packed interface regions, and that within these relatively 
dense clusters, the residues form a dense network of interactions, suggesting that their 
contributions to the stability of the complex should be cooperative (Halperin et al. 
2004; Keskin et al. 2005). A comparison of four different PPIs, with affi nities ranging 
from 2 µM (CheA-CheY complex) to 0.01 pM (barnase-barstar complex ) suggested 
that the extent of connectivity within a cluster of interactions, rather than the size 
of the interface per se, might be the driving force behind tight binding. The degree 
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of connectivity was found to be much higher in the barnase-barstar complex than 
in the other three analyzed. The CheA-CheY interface is characterized by relatively 
few contacts between the proteins and only one medium-sized cluster, whereas the 
barnase-barstar interface has two clusters, one cluster being highly developed and 
forming a very elaborate network of interactions. In the barnase-barstar interaction 
(Schreiber and Fersht 1993), the high affi nity (Kd 0.01 pM) and electrostatically driven 
fast rate of association (kon 6108 s-1 M-1) are likely a response to the strong evolution-
ary pressure on the cell (Bacillus amyloliquefaciens) to develop a potent inhibitor 
(barstar) of the RNase (barnase), to keep the deadly RNase in an inactive form until 
it can be exported from the cell. This strong selection pressure is apparently able to 
overcome the inherent diffi culty in constructing the high level of organization in 
the network of interactions seen at this protein interface (Reichmann et al. 2005). 
These results highlight the importance of higher network organization within protein 
interfaces, and not just of surface complementary principle, in accounting for binding 
affi nity and specifi city. This network or cluster view of protein-protein interactions has 
important implications for inhibitor design, although the focus is often on designing 
molecules to fi ll pockets (“knobs-into-holes”) on the surface of proteins.
Finally, it is important to consider the key role played by water molecules in PPIs. 
Several surveys have shown that water is far more abundant at interfaces, than in the 
cores of folded proteins (Conte et al. 1999). Water-mediated polar interactions are as 
abundant at interfaces as direct protein–protein hydrogen bonds, and they may contrib-
ute signifi cantly to the stability of the assembly (Ikura et al. 2004; Rodier et al. 2005). 
Uncertainties in the location and role of water molecules at PPIs contribute greatly to 
the diffi culties in calculating binding affi nities by computational methods (Wang et al. 
2011), and in attempts to interpret thermodynamic data (binding enthalpy/entropy) in 
structural terms.
Binding driven by association of hydrophobic surfaces is conventionally viewed as 
being driven by favorable entropic contributions, due to release of surface-associated 
water molecules to the bulk solvent (Chandler 2005; Dunitz 1994). However, the 
generality of this view has recently been challenged in a simple model system com-
prising a spherical hydrophobic ligand binding to a solvated hemispherical cavity 
(Baron et al. 2010; Setny et al. 2010). According to MD simulations, the free energy 
of this binding process is not dominated by the direct interaction between the ligand 
and pocket, but by the contributions of water. Contrary to expectation, in this model 
system the binding is driven by enthalpy and opposed by entropy . This was explained 
by the release of water molecules from the pocket, and the loss of entropy as arising 
from the expulsion of disorganized water from the receptor cavity (i.e. cavity water is 
more entropic than bulk water). An interesting experimental study of protein-ligand 
interactions revealed just such a thermodynamic profi le; an increasingly favorable 
enthalpy and increasingly unfavorable entropy as the hydrophobic surface area of 
the ligand increases (Homans 2007; Malham et al. 2005). Another recent survey of 
protein-ligand interactions found that for the majority of small-molecule interactions 
with proteins, the enthalpy change provides the largest favorable contribution to bind-
ing, and contrary to expectation the trend to enhanced affi nity with greater burial of 
apolar surface is, in general, only weakly correlated with a favorable entropy change 
(Olsson et al. 2008).
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17.3 Small-molecule screening approaches
High-throughput screening has often not been very successful for identifying PPI inhibi-
tors (Arkin and Wells 2004; Fry 2006; Toogood 2002). One explanation for this poor 
performance might be that the large compound libraries typically used for screening, 
contain molecules of insuffi cient (or inappropriate) structural diversity. For example, 
relatively small, fl at (sp2 hybridized), aromatic or heteroaromatic compounds, might be 
overrepresented in libraries, because of their perceived likelihood to interact with en-
zyme active sites or G-coupled protein receptors (GPCRs). Mechanistic considerations, 
however (see Section 17.2), suggest that such molecules might not be well suited in the 
search for PPI inhibitors. So what types of property should an ideal screening library 
have? This question was addressed in a recent study in which approximately 15,000 
compounds from three different sources (commercial libraries, academic diversity-
oriented synthesis projects, and natural products) were shown to have quite different 
properties, when tested for their ability to bind a collection of unrelated proteins (Cle-
mons et al. 2010). The study showed that increasing the content of sp3-hybridized and 
stereogenic centers, relative to compounds from commercial sources, improved protein 
binding selectivity and frequency. Not surprisingly, the compounds of highest stereo-
chemical complexity were most often those from natural sources, although continuing 
improvements in organic synthesis methodology (e.g. diversity oriented synthesis) are 
also making such molecules increasingly accessible. The structural and stereochemical 
complexity of natural products relative to small drug-like molecules, and their value 
in the drug-discovery screening exercise, continue to be well argued (Ganesan 2008; 
Harvey 2008; Li and Vederas 2009). It is worth noting that many stereochemically com-
plex natural products are macrocyclic compounds in the molecular weight range 0.5–2 
kDa. Molecules of this size and shape occupy an area of molecular space that nature 
has obviously explored (at least to some extent), but which due to its shear size is much 
more diffi cult to explore thoroughly using diversity-oriented synthesis.
The so-called fragment-based approach is now also being applied to the discovery 
of PPI inhibitors (Coyne et al. 2010; Erlanson 2006; Murray and Blundell 2010). The 
goal here is to build drug leads by identifying small molecular fragments that bind to 
adjacent sites on the protein with µM or even mM affi nity, and then either linking or 
expanding them to improve affi nity and selectivity. The fi rst practical demonstration 
of the approach used SAR by NMR to identify and link small fragments (200–300 Da) 
that bind to FK506-binding protein (Shuker et al. 1996). A related idea called “tether-
ing” aims to discover weakly binding ligands through an intermediary disulfi de tether 
(Erlanson et al. 2000). A native or engineered cysteine in a protein is allowed to react 
reversibly with a library of disulfi de-containing small molecules. The cysteine-captured 
ligands are then identifi ed by MS.
A more recent example of the fragment-based approach is the discovery of inhibitors 
of Bcl-XL , which are important targets in anticancer therapy. The protein Bak adopts an 
amphipathic α helix that binds to Bcl-XL through hydrophobic and electrostatic interac-
tions (crystal structure, PDB 1BXL) (Sattler et al. 1997). Two small-molecule hits that 
target the groove-like binding site on Bcl-XL were found using SAR-by-NMR. These were 
linked and the resulting ligand was optimized in several steps to give ABT-737, with 
subnanomolar affi nity for Bcl-XL (Oltersdorf et al. 2005). A related compound ABT-263 
proved to be orally bioavailable, and advanced into clinical testing in cancer (Park et al. 
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2008). Interestingly, 3D structures of Bcl-XL bound to two low affi nity starting fragments 
(PDB 1YSG), and bound to a high affi nity optimized ligand (PDB 2O2N) have been re-
ported (Bruncko et al. 2007). Upon comparison of these two structures, it is notable that 
the binding site on Bcl-XL has undergone considerable adaptation as the structure of the 
ligand has changed during optimization (Figure 17.1). As a result, the sites on Bcl-XL 
occupied by the two low affi nity ligands have changed considerably when compared to 
the structure of Bcl-XL bound to an optimized ligand, showing that the mechanism of af-
fi nity maturation in this case does not simply involve linking two fragments in adjacent 
binding sites. Clearly, the protein itself adapts considerably as the ligand is changed.
KD  4300 M
KD  300 M
HOOC F
OH
N
N
S
N
H
O
O
O
NH
NO2S
Figure 17.1: Structures of ligands bound to Bcl-xL. A large conformational change in 
the protein Bcl-xL occurs as the ligands change from the complex with low-affi nity 
 inhibitors (left, PDB 1YSG), to that with a high affi nity ligand (middle, PDB 2O2N). The 
protein  conformation is again different when bound to a helical peptide derived from 
an  endogenous BH3 binding partner (right, PDB 1BXL). The small-molecule ligands do 
not mimic the structure of the peptide ligand, but rather trap the protein in a different 
 conformation, binding in deeper cavities with more puckered grooves.
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Another example of adaptivity in a protein-binding site has been observed during 
the discovery and optimization of an IL2 -receptor-α (IL-2Rα) antagonist. A series of 
acylphenylalanine derivatives was discovered in an attempt to mimic the R38−F42 loop 
region of IL-2, one of which was found to be a competitive inhibitor of IL-2/IL-2Rα 
binding with an IC50 of 3 µM (Tilley et al. 1997) (Figure 17.2). Although the acylphe-
nylalanine derivatives were designed to complex with IL-2Rα by emulating residues 
R38 and F42 of the IL-2 ligand, they were instead shown to interact with the ligand 
IL2. From this starting point, new molecules that bind to IL-2 were optimized, with 
dissociation constant in the mid-nanomolar range. These molecules were assembled in 
a fragment-based approach, guided by X-ray structures and medicinal chemistry (Arkin 
et al. 2003; Braisted et al. 2003; Raimundo et al. 2004). Although the small molecules 
were assembled before the structure of the IL-2–IL-2Rα complex had been reported 
(Rickert et al. 2005), they bind close to the center of the receptor contact region on IL-2. 
The contact epitope for the small molecule is about half the size of that for the receptor, 
but the small molecule and the receptor bind to IL-2 with nearly equivalent affi nities. 
The contact surface on IL-2 for binding to IL-2Rα is relatively fl at. By contrast, the small 
molecule traps a conformation of IL-2 in which a groove is present for small-molecule 
binding, and in which a loop of IL-2 has been repositioned to embrace the furanoic acid 
moiety at one end of the small molecule (Figure 17.2). Alanine-scanning mutational 
studies show that the small molecule and the IL-2Rα bind to the same hotspot residues 
on IL-2 (Thanos et al. 2006). Although the structures of the small molecule and IL-2Rα 
differ markedly, the electrostatic potential of the surfaces presented is similar and prob-
ably refl ects a need to establish the electrostatic complementary principle with IL-2. 
Electrostatic and surface-shape complementary principle, as well as specifi c hydrogen-
bonding interactions, probably account for the high selectivity of these interactions.
These studies show that the binding surface on IL-2 is adaptive and can bind to a small 
molecule with high affi nity (Ki = 60 nM) using the same main hot-spot residues used for 
its natural receptor, but again without the benefi t of an “O-ring.” It is notable that the 
design of this series of IL-2-binding small molecules did not require knowledge of the 
structure of the bound receptor complex. Instead, the design was informed by fragment-
binding data and by structures of compounds bound to IL-2, coupled with medicinal 
chemistry and structure–activity relationships (SAR). The small-molecule ligand is not 
an accurate atomic mimic of the receptor, and it would not have been discovered if it 
had been assumed that the precise structure of the receptor-bound form of IL-2 needed 
to be captured. Indeed, the adaptive nature of this protein-protein interface underscores 
again the challenge of applying structure-based strategies that cannot accurately predict 
the dynamic nature of the protein surface (Arkin et al. 2003).
17.4 Protein epitope mimetic approaches
Where 3D structural information is available for PPIs, the design of conformation 
constrained epitope mimetics offers one rational approach to PPI inhibitors. Molecu-
lar recognition involving proteins is typically mediated by surface exposed secondary 
structure elements such as ß turns, ß strands, ß hairpins and α helices. New protein-
binders may be found by devising ways to mimic these important secondary structure 
elements in smaller “semirigid” molecules. Once interesting hits have been identifi ed, 
their properties can be optimized by exploiting the fact that epitope mimetics tend to 
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be modular in structure. They are typically constructed from building blocks, such as 
α- or ß-amino acids or peptoids, which can be linked together using robust and effi cient 
methods. By exchanging building blocks, the mimetic structures can then be varied 
and properties can be optimized, in a combinatorial fashion, using parallel synthetic 
chemistry. One key property, essential for targeting intracellular PPIs, is permeability 
across the cell membrane. Progress has also been made recently in identifying cell 
permeable peptidomimetic PPI inhibitors, suggesting that it may be possible to engineer 
this property into appropriate peptidomimetic scaffolds.
17.4.1 Helix mimetics 
The design of conformationally restrained mimetics of α-helical epitopes continues 
to attract much attention (Garner and Harding 2007; Henchey et al. 2008). Some of 
the approaches used so far to stabilize helical conformations in peptides include the 
use of intramolecular hydrogen-bond surrogates , such as hydrazone or alkenyl links 
(Cabezas and Satterthwait 1999; Chapman et al. 2004; Henchey et al. 2010; Patgiri et 
al. 2008; Vernall et al. 2009; Wang et al. 2005, 2006, 2008), and helical end-capping 
groups (Figure 17.3) (Austin et al. 1997; Kemp and Curran 1988a, 1988b; Kemp and 
O
OMe
HN
O
N
HN
H2N
IL-2
IL-2
IL-2R
IC50  3 M
IC50  60 nM
COOH
O
O
Cl
ClNN
N
O
HN
O
HN H
N
H2N
Figure 17.2: Inhibitors of the IL-2–IL-2Rα interaction. The complex of IL-2 (surface repre-
sentation) and the IL-2Rα chain (ribbon) is shown left, with hot-spot residues on IL-2 shown 
yellow. The acylphenylalanine (left) was optimized to give the high affi nity inhibitor (right) 
shown bound to IL-2. The small molecule traps a conformation of IL-2 in which a binding-
groove is present and in which a loop of IL-2 has been repositioned to embrace the furanoic 
acid moiety at one end of the small molecule. Alanine-scanning mutagenesis shows that the 
small molecule and the receptor bind to the same hotspot residues at an adaptive binding 
surface on IL-2.
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Rothman 1995a, 1995b; Kemp et al. 1995a, 1995b, 1996; Lewis et al. 1998; Maison 
et al. 2001; Obrecht et al. 1999; Schneider and DeGrado 1998). Other methods to 
enhance helicity in peptides include incorporating unnatural amino acids (Andrews 
and Tabor 1999), in particular, α-disubstituted amino acids such as Aib (Venkatraman et 
al. 2001) and other α-alkylated-α-amino acids.
Another approach for the stabilization of α-helical conformations in peptides is by 
side-chain cross-linking , also called “stapling, ,” of i and i+4 or i and i+7 side chains lying 
on the same face of the helix. The earliest reports of cross-linking involved lactam (Felix 
et al. 1988; Geistlinger and Guy 2003; Judice et al. 1997; Mills et al. 2006; Osapay and 
Taylor 1992; Phelan et al. 1997; Shepherd et al. 2006; Sia et al. 2002; Taylor 2002), 
disulfi de (Harrison et al. 2010; Jackson et al. 1991; Leduc et al. 2003) and thioether 
(Brunel and Dawson 2005) bridges, as well as metal-mediated chelation (Beyer et al. 
2004; Ghadiri and Choi 1990; Kelso et al. 2003, 2004; Ruan et al. 1990). Hydrocarbon 
bridges made using olefi n metathesis chemistry have also been reported (Blackwell and 
Grubbs 1998). This concept has been taken a step further by combining within the same 
amino acids the side-chain cross-link and backbone α-methylation (Schafmeister et al. 
2000). In this approach, (R)- and (S)-α-methyl-α-alkenyl amino acids are incorporated 
at i and i+7 positions, respectively, and then linked by ruthenium-catalyzed ring-closing 
metathesis (Figure 17.3). The cross-link results in a stabilized helical conformation in 
the peptide and improved stability of the peptide toward proteolysis. Several applications 
helical epitope
helix
stapling
hydrogen
bond
surrogates
helix
end caps
epitope grafting
to alternate
scaffolds
COOH
O
HOOC
O
HN
O O
O
O
R
N
H
N
H
NH
R
N
H
Y
X
Figure 17.3: Strategies to stabilize or mimic α-helical epitopes. Helical conformations can 
be stabilized in linear peptides, for example, by helix-stapling, by incorporating hydrogen-
bond surrogates, or by adding end-capping groups. Helical epitopes can also be grafted 
onto new scaffolds, including peptide-based and nonpeptidic scaffolds.
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of this technology for helix mimicry have been reported in drug discovery. The confor-
mational constraints imposed by this type of helix cross-linking have favorable effects 
not only on target binding affi nity and proteolytic stability, but surprisingly, also on cell 
membrane permeability. In one example, a hydrocarbon-stapled peptide was designed 
to mimic an amphipathic helix in the pro-apoptotic BH3 domain of the BCL-2 family 
member called BID. The resulting stapled peptide showed not only a much higher heli-
cal content in water, compared to a linear control peptide, but also a higher protease 
stability and a 6-fold higher binding affi nity to BCL-2 (39 vs. 269 nM). Moreover, the 
stapled peptide was apparently taken up by cells in an energy-dependent pinocytotic 
pathway, where it localized with its target at the outer mitochondrial membrane. The 
unmodifi ed control peptide was completely impermeable to the intact cells. The stapled 
peptide mimic of the BH3 domain also specifi cally activated the apoptotic pathway to 
kill leukemia cells, and effectively inhibited the growth of human leukemia xenografts in 
vivo (Walensky et al. 2004). In other examples, a stapled BID BH3 helix was shown to 
bind and activate BAX, a multidomain BCL-2-family protein that resides in the cytoplasm 
(Walensky et al. 2006). And a stapled peptide derived from p53 was shown to bind to 
HDM2 , penetrate cells by an endocytic transport mechanism, and reactivate apopto-
sis in HDM2-overexpressing cells (Bernal et al. 2007). Transcription factors have also 
been rather diffi cult to target using small drug-like molecules. However, a hydrocarbon-
stapled peptide was shown to mimic MAML1 and bind directly to the oncogenic tran-
scription factor NOTCH1 . Treatment of leukaemic cells with the stapled peptide resulted 
in genome-wide suppression of NOTCH-activated genes (Moellering et al. 2009). These 
promising results, targeting a range of diffi cult protein-protein interactions, suggest that 
such stapled α-helical peptide domains may be widely useful in chemical biology, as 
tools for biological studies, and potentially also as drug candidates. Further work will be 
required to assess their pharmacological properties and toxicity, as well as their target 
affi nities and selectivities.
Apart from peptide stapling, α-helical epitopes have been mimicked using other scaf-
folds, including peptoids (Vaz and Brunsveld 2008), ß hairpins (Fasan et al. 2006; Moehle 
et al. 2007; Seitz et al. 2010), ß-peptides and various cyclic scaffolds (Oguri et al. 2005, 
2006), bi- and ter-phenyls (Ernst et al. 2002; Jacoby 2002; Kutzki et al. 2002; Orner et al. 
2001) and related heterocycles (Campbell et al. 2010; Cummings and Hamilton 2010; 
Lee et al. 2011; Saraogi et al. 2010) and templates (Schneider and Kelly 1995).
Stable miniprotein domains also provide a source of scaffolds for epitope grafting and 
mimetic design (Vita 1997; Vita et al. 1998). One interesting example is the family of 
small naturally occurring disulfi de cross-linked peptides belonging to the short-chain 
toxins from scorpion venom, such as charybdotoxin and scyllatoxin (Drakopoulou et al. 
1996; Vita et al. 1995, 1999; Zinn-Justin et al. 1996). These toxins typically contain a 
short α-helical segment at the N-terminal end, cross-linked by three disulfi de bridges to 
a ß-hairpin motif (Figure 17.4). Both the α-helical segment and the ß hairpin provide 
conformation stable segments onto which foreign epitopes can be grafted. For example, 
the ß-hairpin motif has been exploited to generate mimics of an epitope on CD4 , the 
primary cellular receptor for HIV-1 . HIV-1 entry into cells is initiated by the binding of 
the viral glycoprotein gp120 to CD4 on host cells. Crystallographic studies have shown 
that a key component of the epitope on CD4 that interacts with gp120 is a surface 
ß-hairpin loop (the CDR2-like loop) (Kwong et al. 1998). Transplanting this hairpin epi-
tope from CD4 onto the scorpion toxin scaffold afforded, after optimization, mimetics 
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that bind tightly to gp120 and inhibit HIV-1 entry into cells (Huang et al. 2005; Martin 
et al. 2003; Stricher et al. 2008; Vita et al. 1999).
The same scorpion scaffold was also used in a different way, to generate a mimetic 
of the α-helical segment of p53 that interacts with its cellular inhibitor HDM2 (Li et al. 
2008). This study exploited the α-helical segment of the scorpion toxin scaffold. Thus, 
the residues along one face of the scorpion toxin helix were replaced with the topologi-
cally equivalent residues in p53 (F19, L22, W23 and L26), such that the key hydropho-
bic side chains required for interaction with HDM2 are displayed in the correct relative 
orientation (Figure 17.4). With some additional optimization, a p53 mimetic based on 
this toxin scaffold was obtained that bound to HDM2 with submicromolar affi nity. The 
question of cellular membrane permeability was also addressed in this study (Li et al. 
2008). In order to enhance cell permeability, the mimetic was reengineered by replac-
ing fi ve residues near the C terminus with arginines, to create a cluster of eight cationic 
residues. This gave a molecule that, when added to a p53+ cancer cell line, was able to 
kill cells quantitatively and in a p53-dependent manner, apparently due to its ability to 
traverse the cell membrane and inhibit the p53-HDM2 interaction.
Another small folded peptide that has been used for engineering experiments is the 
avian pancreatic polypeptide (aPP) (Hodges and Schepartz 2007). aPP contains 5 turns 
of α helix in its C-terminal half, linked to a 10-residue extended (ß structure) N-terminal 
segment, which is back-folded onto the α helix. The p53 epitope has also been success-
fully grafted onto this aPP scaffold, to create miniprotein inhibitors of the p53-MDM2 
interaction (Kritzer et al. 2006). The cyclotides and conotoxins represent two other 
families of macrocyclic cross-linked peptides, each with great potential as scaffolds in 
protein epitope mimetic design (Cascales and Craik 2010; Clark et al. 2010; Craik et al. 
2006a, 2006b; Green et al. 2007; Henriques and Craik 2010).
Figure 17.4: Both α-helical and ß-hairpin epitopes have been grafted onto the scorpion 
toxin scaffold, resulting in mimetics of p53 for binding to HDM2 (shown left) and of CD4 
binding to gp120 from HIV-1 (shown right).
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A more recent trend is toward the design of novel folding architectures, or “foldam-
ers ,” that adopt regular structural elements akin to α helices and ß structure, but built 
using other types of building blocks (i.e. not α-amino acids) (Goodman et al. 2007; 
Guichard and Huc 2011; Hill et al. 2001; Smith et al. 2011). Stable helix-like conforma-
tions have been characterized in oligomers prepared from N-alkylglycines (peptoids) 
(Fowler and Blackwell 2009) and from ß- and γ-amino acids (Horne and Gellman 2008; 
Seebach et al. 2004). The ß-peptides have been the most studied family of peptidomi-
metic foldamers, but whereas many short ß-peptides adopt well-defi ned conformations 
in organic solvents, additional helix-stabilizing elements (e.g. ring constraints or helix 
stapling) are required for stable folds to occur in aqueous solution (Appella et al. 1999; 
Vaz et al. 2008). Aromatic and aliphatic N,N’-linked oligoureas have also been de-
signed to fold and/or self-assemble in a controlled manner (Fischer and Guichard 2010). 
The development of foldamers with heterogeneous backbones formed by combining 
multiple residue types (mixed α/ß-peptides, oligo-urea/amides) has also been reported 
(Claudon et al. 2010; Horne and Gellman 2008).
Some of these novel foldamer scaffolds have also been applied successfully to PPI in-
hibitor design. For example, ß-amino acids have been incorporated into a mimic of the 
helical coiled-coil heptad repeat region 2 (HR2) of gp41 from HIV-1. This HR2 region 
must interact with the HR1 heptad repeat region before fusion of the viral and target 
cell membranes can occur. The chimeric α/β-peptides were shown to mimic structural 
and functional properties of the critical α-helical HR2 epitope in gp41. Biophysical and 
crystallographic studies, and results from cell-fusion and virus-infectivity assays, col-
lectively indicate that the gp41-mimetic α/β-peptides effectively block HIV-cell fusion 
via a mechanism comparable to that of gp41-derived α-peptides such as T20 (Fuzeon) 
(Horne et al. 2009). In a related study, a series of ß3-decapeptides, also based on gp41, 
were designed with a ß-peptide 14-helical conformation stabilized by macro dipole 
neutralization and side chain-side chain salt bridges (Stephens et al. 2005). The peptide 
mimetics were shown to inhibit syncytia formation in cell culture, again by blocking 
PPIs important for infection by HIV-1. A similar viral-host cell fusion mechanism is also 
exploited by other viruses (Eckert and Kim 2001). Thus, helical ß-peptides have been 
designed that target in a similar way the coiled-coil PPIs that occur during infection by 
human cytomegalovirus (English et al. 2006).
ß-Peptides have also been designed to mimic helical epitopes in the tumor suppressor 
protein p53 and in antiapoptotic BCL-2 family members such as BH3. For example, salt 
bridge-stabilized 14-helical ß-peptides have been described, bearing on one face of 
the helix residues required for binding to MDM2 (Kritzer et al. 2004). The most potent 
ß-peptides were reported to bind MDM2 and MDMX, and inhibit the p53-MDM2/
MDMX PPI, with nanomolar affi nities in a direct fl uorescence polarization assay (Mi-
chel et al. 2009). In later studies, ß-peptides with hydrocarbon and diether staples 
(bridges) were prepared that not only potently inhibit the p53-MDM2 interaction, but 
also are taken-up by mammalian cells far more effi ciently than unbridged analogues 
(Bautista et al. 2010). In the case of the BH3/Bcl-xL interaction, sequence rather than 
structural information on the interaction of BH3 domains with Bcl-xL has been exploited 
to design inhibitors based on chimeric α/ß-peptides (Horne et al. 2008). The approach 
involved replacing subsets of regularly spaced α residues with β3 residues bearing the 
original side chains. Each α/β-peptide contains an ααβαααβ backbone repeat, which 
is derived from the heptad pattern common among α-peptide sequences that form α 
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helices with a well-developed “stripe” of hydrophobic side chains running along one 
side. This approach led to α/ß-peptides with comparable binding affi nity for the protein 
target and substantially improved proteolytic stability. A crystal structure of a complex 
between one α/ß-peptide foldamer and the protein partner Bcl-xL shows that the fol-
damer adopts a helical conformation and is oriented within the BH3 recognition groove 
in a similar fashion to natural BH3 domains (Lee et al. 2009) (Figure 17.5). The C-
terminal α-peptide portion is α helical, whereas the α/ß segment adopts a characteristic 
14/15-helical structure with some cyclic ß-amino acid residues (trans-2-aminocyclo-
pentane carboxylic acid) making contacts with the protein surface. The helix formed by 
the Bcl-xL-bound foldamer features a network of backbone C=O(i)H-N(i+4) H-bonds 
over nearly the entire length of the oligomer. The crystal data suggest that the foldamer 
achieves high affi nity in part by mimicking the three-dimensional display of the canoni-
cal side chains projected by natural BH3 domains, however, the β-residue contacts may 
also contribute signifi cantly to foldamer affi nity.
17.4.2 ß-Hairpin mimetics
ß structure and in particular ß hairpins also occur frequently in protein-protein rec-
ognition epitopes. Not surprisingly, therefore, the design of hairpin mimetics has also 
attracted great interest. ß-Hairpin loops are found in the antigen-binding sites of anti-
bodies and the ligand binding sites of many cytokine receptors and polypeptide growth 
factors, as well as in many integrins and viral proteins, a wide variety of smaller host-
defence peptides such as defensins, venom toxins such as ω-conotoxin and three-fi nger 
snake toxins, in cyclotides, and in Bowman-Birk and related proteinase inhibitors, to 
name but a few. Naturally occurring ß-hairpin motifs possess a remarkable degree of 
structural diversity, due to variations in loop size, variations in the hairpin register, due 
to the occurrence of ß-bulges within the ß strands, and of course due to variations in 
sequence. The register of a ß hairpin defi nes which pairs of cross-strand amino acids 
occupy hydrogen-bonding (HB), rather than non-hydrogen-bonding (NHB), positions. 
This in turn determines which amino acid side chains are displayed on the same face of 
the hairpin (Figure 17.6).
Figure 17.5: Chimeric α/ß-peptide (right) designed to mimic an α-helical epitope (left) in 
the BH3 domain for binding to Bcl-xL.
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ß-Hairpin loop structures can be stabilized in linear peptides using disulfi de bridges. 
This approach has been particularly valuable in phage-display technology to select 
peptides that bind to specifi c protein targets (Sidhu et al. 2000). Spectacular examples 
have been reported of disulfi de-bridged hairpin-loop peptides selected by phage display 
that can mediate (agonist) or inhibit PPIs. For example, by screening a random phage 
library against the immobilized erythropoietin receptor (EPO-R), a disulfi de-bridged 
peptide [GGTYSCHFGPLTWVCKPQGG] was found, that binds to EPO-R in a ß-hairpin 
conformation (Figure 17.7) (Livnah et al. 1996; Wrighton et al. 1996). This hairpin 
peptide mimics the helical cytokine EPO by interacting with the EPO-binding site on 
the receptor, causing dimerization of the extracellular domain. As a result, both EPO 
and the peptide induce a similar signalling cascade of phosphorylation events and cell 
cycle progression in EPO responsive cells. In another example, a phage-library of cyclic 
peptides was screened for binding to the constant fragment (Fc) of immunoglobulin 
G (IgG) (DeLano et al. 2000). A disulfi de bridged hairpin peptide was isolated that 
interacts with the Fc at a highly accessible adaptive and hydrophobic site that also is 
used by other Fc-binding proteins, including protein A, protein G, rheumatoid factor 
and the neonatal Fc-receptor. Phage display is now a well-established and powerful 
approach for selecting peptides and proteins with novel binding functions from large 
 combinatorial libraries (Sidhu et al. 2003).
A disulfi de bridge, however, has disadvantages, because it can be cleaved in vivo by 
reaction with a free thiol group, and the disulfi de link has many degrees of rotational 
freedom, which in the absence of other stabilizing interactions (Russell et al. 2002), 
can make it diffi cult to stabilize discrete hairpin registers or conformations. ß-Hairpin 
conformations have been successfully stabilized in linear peptides by exploiting tryp-
tophan zipper motifs (π-π-stacking interactions between cross-ß-strand tryptophans at 
NHB positions), and related interactions (Eidenschink et al. 2009; Russell et al. 2002; 
Wu et al. 2010b). The residues in the turn region have a strong infl uence upon ß-hairpin 
Figure 17.6: The register of a ß-hairpin loop defi nes which pairs of cross-strand amino acids 
occupy hydrogen-bonding (HB) (indicated with blue dashed lines) and NHB.
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stability in linear peptides. Turns formed by Asn-Gly, D-Pro-Gly, Aib -Gly and Aib-D-Pro 
are strong promoters of ß-hairpin formation due to their propensity to form type-I’ or -II’ 
turns (Raghavender et al. 2010; Rai et al. 2007), which match the preferred right-handed 
twist of a hairpin. Other building blocks have been incorporated into turn regions and 
into the ß-strand regions, including, for example, the 1,2-dihydro-3(6H)-pyridinyl unit 
that favors extended conformations (Phillips et al. 2005). A novel hairpin-capping motif 
was described recently, which appears to overcome the problem of fraying at the ends 
of the ß strands in hairpin motifs in linear peptides (Kier et al. 2010). The capping 
motif comprises synergistic stacking and hydrogen-bonding interactions between an N-
terminal alkanoyl-Trp and a C-terminal -TrpThrGly- motif, which effectively tie together 
the ß strands as long as the Trp residues are at terminal NHB positions.
Stable ß-hairpin scaffolds can also be achieved by linking together the N  and C ter-
mini, to produce macrocyclic hairpin structures. Nature has also exploited this strategy, 
as evidenced by macrocyclic natural products such as gramicidin S , which has a hairpin 
structure with two D-Phe-L-Pro units marking the turn regions. Other approaches to 
macrocycles with stable parallel ß-sheet scaffolds have also been described recently 
(Freire and Gellman 2009; Woods et al. 2007).
Alternatively, ß-hairpin structures in naturally occurring peptides and proteins can be 
mimicked by transplanting the hairpin loop onto an appropriate (semi)-rigid template; 
the so-called protein epitope mimetic (PEM) technology (Robinson 2008; Robinson et 
al. 2008). The dipeptide D-Pro-L-Pro has proved to be an extremely useful template in 
ß-hairpin mimetic design (Figure 17.8). This dipeptide adopts a rigid type-II’ ß turn, 
which is ideal to initiate antiparallel strands held together by registered cross-strand hy-
drogen bonds. Upon transplanting the loop from the protein of interest, the cross-strand 
residue pair directly attached to the D-Pro-L-Pro template then occupay a hydrogen-
bonding position. In this way, accurate structural mimetics have been produced of CDR 
loops found in antibodies (Favre et al. 1999), of a ß-hairpin loop in Tat bound to HIV-1 
TAR-RNA (Athanassiou et al. 2004,  2007; Davidson et al. 2009; Lalonde et al. 2011; 
Leeper et al. 2005), of protease inhibitors related to the Bowman-Birk family (Descours 
Figure 17.7: A disulfi de bridged ß-hairpin peptide selected by phage display (right) mimics 
the helical cytokine EPO (left) in binding to and activating the EPO-receptor.
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et al. 2002), and of cationic host-defence peptides related to protegrin-I (Robinson et 
al. 2005; Shankaramma et al. 2002, 2003; Srinivas et al. 2010) and polyphemusin (De-
Marco et al. 2006). In another example, a 13-residue disulfi de cross-linked loop taken 
from a phage display peptide that binds a human antibody Fc fragment (discussed previ-
ously in this section) (DeLano et al. 2000) was transplanted onto a D-Pro-L-Pro template 
(Dias et al. 2006). The resulting 13-mer loop was shown to adopt a well-defi ned ß-
hairpin structure, which includes a bulge in the second strand close to the turn region, 
with the unusual result that side-chains of two adjacent residues point to the same side 
of the hairpin.
The interest in ß-hairpin mimetics is enhanced further by the realization that a hairpin 
scaffold can also be exploited to mimic α-helical epitopes. Thus, the distance between 
the Cα atoms of two residues i and i+2 along one strand of a hairpin is very close to that 
between the Cα atoms of two residues i and i+4 on one face of an α helix. Using this 
information it was possible to design a ß hairpin to mimic the pharmacophore within a 
helical peptide derived from p53 (Figure 17.9), which is involved in binding to its in-
teracting protein HDM2 (Fasan et al. 2004, 2006). Template-bound ß-hairpin mimetics 
were found that bind with nanomolar affi nity to HDM2 (Grässlin et al. 2009). A crystal 
structure of one mimetic bound to HDM2 confi rmed that the hairpin scaffold presents 
three side chains along the fi rst strand of the hairpin for binding to HDM2, just like the 
corresponding three residues situated on one face of the helical p53 (Figure 17.9). 
In addition, residues in the second ß strand of the mimetic make additional favorable 
contacts with HDM2, which are not seen in the p53-HDM2 complex. Other examples 
of hairpin mimicry of helical epitopes have been reported more recently, based on the 
interactions of Rev protein to RRE-RNA , and of a helical epitope in the chemokine 
receptor CCR5 that binds to the HIV-1 glycoprotein gp120 (Moehle et al. 2007; Seitz et 
Figure 17.8: ß-Hairpin mimetics can be produced by transplanting the hairpin loop from a 
protein of interest (left), onto a hairpin-stabilizing template, such as the dipeptide D-Pro-L-
Pro (center), to give a cyclic ß-hairpin PEM (right).
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al. 2010). These examples suggest that the hairpin scaffold might be widely applicable 
in the design of helical epitope mimetics.
The macrocyclic ß-hairpin mimetics described previously in this section are con-
structed from building blocks that can be linked together using robust and effi cient 
solid-phase synthesis methods. By exchanging building blocks, the mimetic structures 
can be quickly varied and their properties optimized, in an effi cient combinatorial fash-
ion, using parallel synthetic chemistry (Jiang et al. 2000). The ease with which analogues 
can be produced in this way, contrasts with the diffi culties that often exist in synthesiz-
ing analogues of complex natural products of similar size. The variables for creating 
combinatorial libraries include the size of the ß-hairpin loop, the types of amino acid 
building blocks, as well as the template (Figure 17.10). The proteinogenic α-amino 
acids often make convenient starting points for mimetic design, but may be exchanged 
for any of a large number of known nonproteinogenic amino acids, or related building 
bocks. This provides great scope for optimizing drug-like properties (ADMET), as well 
as target affi nity and specifi city, within a lead series. This point is illustrated by recent 
examples that have led to clinical drug candidates (Obrecht et al. 2011; Robinson et 
al. 2008). In one case, a family of PEM molecules modeled on the naturally occur-
ring cationic antimicrobial peptide protegrin I (PG-I) was discovered using the PEM 
technology. The lead compound L27–11 is a potent antibiotic with a novel mechanism 
of action, which is active in the nanomolar range against Pseudomonas species and, 
in particular, the important human pathogen Pseudomonas aeruginosa (Srinivas et al. 
2010). This family of PEM molecules does not lyse cells, but rather, they are able to tar-
get a bacterial ß-barrel outer membrane (OM) protein called LptD , which is essential for 
the assembly of the outer leafl et of the OM in many gram-negative bacteria (Chng et al. 
2010; Ruiz et al. 2009; Sperandeo et al. 2009). When the function of LptD is blocked, 
Figure 17.9: ß-Hairpin mimetics can also be used to mimic the α-helical epitope in p53. 
A crystal structure of one hairpin mimetic bound to HDM2 is shown (left). The cyclic pep-
tide scaffold is used to display hot-spot residues lying along one face of an α-helical epitope 
in p53, which are important for binding to HDM2 (right).
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OM biogenesis is disrupted. The discovery of L27–11 involved an iterative process of 
library synthesis and screening, in which an initial hit was identifi ed by PEM library 
synthesis and screening for antimicrobial activity. The optimal hit from each library was 
used as a starting point for the synthesis and testing of variations in a subsequent library. 
The same procedure was also followed to optimize the drug-like properties of L27–11, 
including the plasma stability, target selectivity, and toxicology. This process resulted 
in the clinical lead candidate POL7080 (Srinivas et al. 2010). The safety of mimetic 
POL7080 is now being tested in healthy humans in a phase I clinical study, but it is clear 
already that this mimetic represents the fi rst in a new class of antibiotics active against 
gram-negative bacteria.
A second example is provided by a family of PEM molecules that were based upon 
the naturally occurring peptide polyphemusin II, an 18-amino-acid peptide isolated 
from the American horseshoe crab (Limulus polyphemus), which inhibits the chemokine 
and G-coupled protein receptor CXCR4 . Based on the solution structure of polyphe-
musin II, several PEM molecules were designed and optimized in biological assays. This 
led to highly potent and selective CXCR4 antagonist such as POL3026, POL5551 and 
POL6326 (DeMarco et al. 2006; Robinson et al. 2008). POL6326 has now successfully 
moved into a phase II clinical trial for autologous stem cell transplantation in newly di-
agnosed multiple myeloma patients. Interim results from this study show that POL6326 
is safe, well tolerated and effi cient in mobilizing hematopoetic stem cells. Recently, an 
variables for optimization
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Figure 17.10: The structures and properties of ß-hairpin protein epitope mimetics (PEMs) 
can be varied and optimized through library synthesis and screening. Some of the variables 
for library design are indicated.
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X-ray structure revealed how a very closely related ß-hairpin-shaped peptide binds to 
an engineered form of CXCR4 (Wu et al. 2010a). The ß hairpin occupies a binding site 
on CXCR4 formed by residues in the inward-facing protruding walls of the seven trans-
membrane helical bundle, several extracellular loops, and the N-terminal segment. A 
network of polar, hydrogen-bonding and hydrophobic contacts between the ligand and 
the receptor are responsible for the specifi c high affi nity interaction. The close structural 
similarity between this bound ligand and POL3026, suggests that the macrocyclic ß-
hairpin mimetic should interact with CXCR4 in a similar manner.
The genomic and proteomic revolutions continue to provide us with an ever-
increasing number of mechanistic insights into biological signalling pathways, and 
potential targets for inhibition using small molecules. Unfortunately, many of the 
genes and gene products that are often most attractive from a biological perspec-
tive for targeting using small molecules are also often the least tractable from the 
perspective of small drug-like molecules. Such targets typically include proteins that 
participate in PPIs or protein-nucleic acid interactions, which are often deemed to be 
“undruggable” within major pharmaceutical companies (Arkin and Wells 2004; Hop-
kins and Groom 2002). The diffi culty in addressing “undruggable ” targets using small 
drug-like molecules (Wells and McClendon 2007) provides a powerful motivation to 
explore new scaffolds and new regions of molecular space to overcome this problem. 
The protein epitope mimetics described in this article are positioned within a huge 
and relatively unexplored region of molecular space, having a size and complexity 
between that of traditional small drug-like molecules and much larger ‘biologics’, 
such as antibodies. It is clear already that protein epitope mimetics can provide a rich 
source of interesting leads for use in chemical biology, as well as drug and vaccine 
research. And the scope for further innovation and discovery in this fi eld appears to 
be immense.
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